MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 522416 | Name: TRAM-34
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TRAM-34 is a highly selective blocker of intermediate conductance Ca2+-activated K+ channels (KCa3.1) that has been shown to suppress the reactivation of lymphocytes by mitogenic stimuli without blocking cytochrome P450.

Chemical Structure

TRAM-34
TRAM-34
CAS#289905-88-0

Theoretical Analysis

MedKoo Cat#: 522416

Name: TRAM-34

CAS#: 289905-88-0

Chemical Formula: C22H17ClN2

Exact Mass: 344.1080

Molecular Weight: 344.84

Elemental Analysis: C, 76.63; H, 4.97; Cl, 10.28; N, 8.12

Price and Availability

Size Price Availability Quantity
10mg USD 230.00 2 Weeks
25mg USD 385.00 2 Weeks
50mg USD 630.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
TRAM-34; TRAM34; TRAM 34
IUPAC/Chemical Name
1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole
InChi Key
KBFUQFVFYYBHBT-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H17ClN2/c23-21-15-8-7-14-20(21)22(25-17-9-16-24-25,18-10-3-1-4-11-18)19-12-5-2-6-13-19/h1-17H
SMILES Code
C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CC=N4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 344.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Glaser N, Chu S, Weiner J, Zdepski L, Wulff H, Tancredi D, ODonnell ME. Effects of TRAM-34 and minocycline on neuroinflammation caused by diabetic ketoacidosis in a rat model. BMJ Open Diabetes Res Care. 2022 May;10(3):e002777. doi: 10.1136/bmjdrc-2022-002777. PMID: 35584854; PMCID: PMC9119135. 2: Schilling T, Eder C. TRAM-34 inhibits nonselective cation channels. Pflugers Arch. 2007 Jul;454(4):559-63. doi: 10.1007/s00424-007-0232-4. Epub 2007 Feb 23. PMID: 17318643. 3: Guo SJ, Wang T, Jia LQ, Li DD, Shen YC, Xu D, Wen FQ. TRAM-34 attenuates hypoxia induced pulmonary artery smooth muscle cell proliferation. Eur Rev Med Pharmacol Sci. 2015 Sep;19(18):3515-21. PMID: 26439051. 4: Hamad A, Ozkan MH. The KCa3.1 Channel Blocker TRAM-34 and Minocycline Prevent Fructose-Induced Hypertension in Rats. Am J Hypertens. 2024 Nov 15;37(12):995-1002. doi: 10.1093/ajh/hpae115. PMID: 39189991; PMCID: PMC11664185. 5: Stransky N, Ganser K, Quintanilla-Martinez L, Gonzalez-Menendez I, Naumann U, Eckert F, Koch P, Huber SM, Ruth P. Efficacy of combined tumor irradiation and KCa3.1-targeting with TRAM-34 in a syngeneic glioma mouse model. Sci Rep. 2023 Nov 23;13(1):20604. doi: 10.1038/s41598-023-47552-4. PMID: 37996600; PMCID: PMC10667541. 6: Zeng B, Huang Y, Chen S, Xu R, Xu L, Qiu J, Shi F, Liu S, Zha Q, Ouyang D, He X. Dextran sodium sulfate potentiates NLRP3 inflammasome activation by modulating the KCa3.1 potassium channel in a mouse model of colitis. Cell Mol Immunol. 2022 Aug;19(8):925-943. doi: 10.1038/s41423-022-00891-0. Epub 2022 Jul 7. PMID: 35799057; PMCID: PMC9338299. 7: Agarwal JJ, Zhu Y, Zhang QY, Mongin AA, Hough LB. TRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activity. PLoS One. 2013 May 7;8(5):e63028. doi: 10.1371/journal.pone.0063028. PMID: 23667566; PMCID: PMC3646888. 8: Fuchs AA, Balne PK, Giuliano EA, Sinha NR, Mohan RR. Evaluation of a novel combination of TRAM-34 and ascorbic acid for the treatment of corneal fibrosis in vivo. PLoS One. 2022 Jan 10;17(1):e0262046. doi: 10.1371/journal.pone.0262046. PMID: 35007294; PMCID: PMC8746773. 9: Lin H, Zheng C, Li J, Yang C, Hu L. Ca2+ -activated K+ channel-3.1 blocker TRAM-34 alleviates murine allergic rhinitis. Int Immunopharmacol. 2014 Dec;23(2):642-8. doi: 10.1016/j.intimp.2014.10.017. PMID: 25466273. 10: Xie H, Lu J, Zhu Y, Meng X, Wang R. The KCa3.1 blocker TRAM-34 inhibits proliferation of fibroblasts in paraquat-induced pulmonary fibrosis. Toxicol Lett. 2018 Oct 1;295:408-415. doi: 10.1016/j.toxlet.2018.07.020. Epub 2018 Jul 20. PMID: 30036685. 11: Naziris N, Pippa N, Sereti E, Chrysostomou V, Kędzierska M, Kajdanek J, Ionov M, Miłowska K, Balcerzak Ł, Garofalo S, Limatola C, Pispas S, Dimas K, Bryszewska M, Demetzos C. Chimeric Stimuli-Responsive Liposomes as Nanocarriers for the Delivery of the Anti-Glioma Agent TRAM-34. Int J Mol Sci. 2021 Jun 10;22(12):6271. doi: 10.3390/ijms22126271. PMID: 34200955; PMCID: PMC8230631. 12: Jiang TH, Huang ZG. [Effects of TRAM-34 on Proliferation and Invasion of Leukemia Cell Line HL-60]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Feb;25(1):104-109. Chinese. doi: 10.7534/j.issn.1009-2137.2017.01.018. PMID: 28245384. 13: Seo CH, Cui HS, Kim JB. Altered KCa3.1 expression following burn injury and the therapeutic potential of TRAM-34 in post-burn hypertrophic scar formation. Transl Res. 2021 Oct;236:133-146. doi: 10.1016/j.trsl.2021.04.007. Epub 2021 Apr 24. PMID: 33905948. 14: Freise C, Querfeld U. Inhibition of vascular calcification by block of intermediate conductance calcium-activated potassium channels with TRAM-34. Pharmacol Res. 2014 Jul;85:6-14. doi: 10.1016/j.phrs.2014.04.013. Epub 2014 May 6. PMID: 24813858. 15: García-López C, Rodríguez-Calvo-de-Mora M, Borroni D, Sánchez-González JM, Romano V, Rocha-de-Lossada C. The role of matrix metalloproteinases in infectious corneal ulcers. Surv Ophthalmol. 2023 Sep-Oct;68(5):929-939. doi: 10.1016/j.survophthal.2023.06.007. Epub 2023 Jun 21. PMID: 37352980. 16: Mohr CJ, Steudel FA, Gross D, Ruth P, Lo WY, Hoppe R, Schroth W, Brauch H, Huber SM, Lukowski R. Cancer-Associated Intermediate Conductance Ca2+-Activated K⁺ Channel KCa3.1. Cancers (Basel). 2019 Jan 17;11(1):109. doi: 10.3390/cancers11010109. PMID: 30658505; PMCID: PMC6357066. 17: Guo S, Shen Y, He G, Wang T, Xu D, Wen F. Involvement of Ca2+-activated K+ channel 3.1 in hypoxia-induced pulmonary arterial hypertension and therapeutic effects of TRAM-34 in rats. Biosci Rep. 2017 Jul 27;37(4):BSR20170763. doi: 10.1042/BSR20170763. PMID: 28679649; PMCID: PMC5529208. 18: Glaser N, Little C, Lo W, Cohen M, Tancredi D, Wulff H, O'Donnell M. Treatment with the KCa3.1 inhibitor TRAM-34 during diabetic ketoacidosis reduces inflammatory changes in the brain. Pediatr Diabetes. 2017 Aug;18(5):356-366. doi: 10.1111/pedi.12396. Epub 2016 May 13. PMID: 27174668. 19: Koch P, Schollmeyer D. 1-[(2-Chloro-phen-yl)di-phenyl-meth- yl]-1H-pyrazole. IUCrdata. 2024 Dec 3;9(Pt 12):x241152. doi: 10.1107/S2414314624011520. PMID: 39777012; PMCID: PMC11701755. 20: Bonito B, Sauter DR, Schwab A, Djamgoz MB, Novak I. KCa3.1 (IK) modulates pancreatic cancer cell migration, invasion and proliferation: anomalous effects on TRAM-34. Pflugers Arch. 2016 Nov;468(11-12):1865-1875. doi: 10.1007/s00424-016-1891-9. Epub 2016 Oct 17. PMID: 27752766.